| 摘要 |
<p>The disclosure relates to novel pentanor prostaglandin analogues, for example 15-(5-chloroindan-2-yl)-9 alpha ,11 alpha ,15-trihydroxy-16,17,18,19,20-pentanor-5-cis,13-trans-prostadienoic acid and 15-(5-chloroindan-2-yl)-11 alpha ,15-dihydroxy-9-oxo-16,17,18,19,20-pentanor-5-cis,13-trans-prostadienoic acid and the 1-ester and 1-alcohol derivatives thereof, to a process for their manufacture, to compositions containing them, and to their use in a method of inducing luteolysis.</p> |
